Azole resistance in aspergillus fumigatus-current epidemiology and future perspectives

Current Fungal Infection Reports

Volumn 5, Issue 3, 2011, Pages 168-178

  Alanio, Alexandre ^a   Cordonnier, Catherine ^b   Bretagne, Stéphane ^a  

^a INSTITUT PASTEUR   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

14? demethylase; Acquisition; Antifungal drugs; Aspergillus fumigatus; Azoles; Chronic aspergillosis; Cyp51A; Emergence; Environment; Erg11; Fungicides; Genotype; Invasive aspergillosis; Itraconazole; Mutation; Pesticides; Posaconazole; Resistance; Substitution; Target modification; Triazoles; Voriconazole

Indexed keywords

PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CROSS RESISTANCE; FUNGAL GENE; FUNGUS TRANSMISSION; GENE MUTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; NONHUMAN; PREVALENCE;

EID: 80755182326     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0061-y     Document Type: Article

References (94)

1. Nam H, Jeon K, Um S, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14:e479-82.
2. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. These are the recommendations of the Infectious Diseases Society of America for the treatment of aspergillosis. (Pubitemid 351265310)
3. Lehrnbecher T, Frank C, Engels K, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61:259-65.
4. Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med. 2010;16:242-50.
5. Andes D. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Updat. 2004;7:185-94. (Pubitemid 39024519)
6. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-11. (Pubitemid 351269158)
7. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417-27.
8. Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and metaanalysis. Lancet Infect Dis. 2009;9:89-96.
9. Bretagne S. Advances and prospects for molecular diagnostics of fungal infections. Curr Infect Dis Rep. 2010;12:430-6.
10. Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol. 2003;119:854-8. (Pubitemid 37047847)
11. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002;21:161-72.
12. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol. 2005;131:201-7. (Pubitemid 43899686)
13. Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192-8. (Pubitemid 38971489)
14. Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol. 2005;43:4902-4. (Pubitemid 41298308)
15. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011;46:709-18. This paper summarizes the recommendations of the European Conference on Infections in Leukemia for the management of aspergillosis.
16. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Micro. 2005;3:547-56. (Pubitemid 40903878)
17. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364-8. (Pubitemid 27231443)
18. Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116-8.
19. Snelders E, van der Lee HAL, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. Plos Med 2008; 5: e219. This article describes for the first time the emergence of resistant isolates in The Netherlands.
20. Hong S, Shin H, Hong J, et al. New taxa of Neosartorya and Aspergillus in Aspergillus section Fumigati. Antonie van Leeuwenhoek. 2008;93:87-98.
21. Balajee SA, Gribskov JL, Hanley E, et al. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell. 2005;4:625-32. (Pubitemid 40383765)
22. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, et al. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52:1244-51. (Pubitemid 351521983)
23. Pfaller MA, Messer SA, Boyken L, et al. in vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol. 2008;46:2568-72.
24. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRYAntimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-7. (Pubitemid 34260347)
25. Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell. 2006;5:1705-12. (Pubitemid 44622598)
26. Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47:877-84.
27. Alanio A, Beretti J, Dauphin B, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species. Clin Microbiol Infect. 2011;17:750-5.
28. Etienne KA, Kano R, Balajee SA. Development and validation of a microsphere-based Luminex assay for rapid identification of clinically relevant aspergilli. J Clin Microbiol. 2009;47:1096-100.
29. Lass-Flörl C: in vitro susceptibility testing in Aspergillus species: an update. Future Microbiol 2010; 5: 789-799. This paper provides recent reviews of antifungal drug susceptibility testing.
30. Pfaller MA, Messer SA, Mills K, et al. in vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol. 2000;38:3359-61.
31. Verweij PE, Howard SJ, Melchers WJG, et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-147. This paper proposes breakpoints to define resistance in Aspergillus fumigatus using EUCAST methodology.
32. Warn PA, Sharp A, Morrissey G, et al. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and-resistant strains of Aspergillus fumigatus. Int J Antimicrob Agents. 2010;35:146-51.
33. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother. 2008;52:3504-11.
34. Dannaoui E, Borel E, Persat F, et al. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. J Med Microbiol. 1999;48:1087-93.
35. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat. 2005;8:344-58. (Pubitemid 43358058)
36. da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, et al. in vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48:4405-13. (Pubitemid 39434904)
37. Slaven J, Anderson M, Sanglard D, et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fung Genet Biol. 2002;36:199-206.
38. Nascimento AM, Goldman GH, Park S, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003;47:1719-26. (Pubitemid 36548560)
39. Willger SD, Puttikamonkul S, Kim K, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 2008;4:e1000200.
40. Richie DL, Hartl L, Aimanianda V, et al. A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus. PLoS Pathog. 2009;5:e1000258.
41. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol. 2001;39:2431-8. (Pubitemid 32606215)
42. Warrilow AGS, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (Cyp51) isoenzymes A and B. Antimicrob Agents Chemother. 2010;54:4225-34.
43. Mellado E, Garcia-Effron G, Buitrago M, et al. Targeted gene disruption of the 14-? sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob Agents Chemother. 2005;49:2536-8. (Pubitemid 40734499)
44. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, et al. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47:1120-4.
45. Kelly SL, Lamb DC, Corran AJ, et al. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8, 24(28)-dien-3 beta, 6 alpha-diol. Biochem Biophys Res Commun. 1995;207:910-5.
46. Mann PA, Parmegiani RM, Wei S, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother. 2003;47:577-81. (Pubitemid 36158085)
47. Mellado E, García-Effrón G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897-904. (Pubitemid 46903071)
48. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747-50. (Pubitemid 38823458)
49. Alcazar-Fuoli L, Mellado E, Cuenca-Estrella M, et al. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med Mycol. 2011;49:276-84.
50. Escribano P, Recio S, Peláez T, et al. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55:2460-2.
51. Verweij P, van der Linden J, Camps S, et al. A new resistance mechanism from environmental origin conferring to voriconazole resistance has emerged in clinical Aspergillus fumigatus isolates in the Netherlands [abstract]. Presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, Massachusetts; September 12-15, 2010.
52. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus Cyp51A protein. Antimicrob Agents Chemother. 2011;55:2483-6.
53. Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48:568-74. (Pubitemid 38141718)
54. Gollapudy R, Ajmani S, Kulkarni SA. Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase "A" with azole antifungals. Bioorg Med Chem. 2004;12:2937-50. (Pubitemid 38622128)
55. Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in Aspergillus fumigatus Cyp51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425-30.
56. Denning DW, Radford SA, Oakley KL, et al. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997;40:401-14. (Pubitemid 27437961)
57. Denning DW, Park S, Lass-Flörl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123-9.
58. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076. This paper shows the increasing prevalence of azole-resistant isolates, mainly recovered in patients treated for chronic aspergillosis in the United Kingdom.
59. Martinez M, Cloud G, Chen V, et al. Itraconazole and amphotericin B resistance 1987-2009 in clinical Aspergillus fumigatus in northern California [poster #40]. Presented at 4th Advances Against Aspergillosis. Rome, Italy: February 4-6, 2010.
60. Krishnan-Natesan S: Antifungal susceptibility pattern of Aspergillus fumigatus isolated from clinical specimens in Detroit Medical Center (DMC): Rising frequency of high MIC of azoles (2003-06). Presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, Massachusetts; September 12-15, 2010.
61. Moore CB, Sayers N, Mosquera J, et al. Antifungal drug resistance in Aspergillus. J Infect. 2000;41:203-20. (Pubitemid 32051038)
62. Howard SJ, Webster I, Moore CB, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28:450-3. (Pubitemid 44740492)
63. Chryssanthou E. in vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis. 1997;29:509-12.
64. Thors VS, Bierings MB, Melchers WJG, et al. Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy. Pediatr Infect Dis J. 2011;30:268-70.
65. Bellete B, Raberin H, Morel J, et al. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol. 2010;48:197-200.
66. van der Linden JWM, Jansen RR, Bresters D, et al. Azoleresistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111-3.
67. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3271-5.
68. Amorim A, Guedes-Vaz L, Araujo R. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents. 2010;35:396-9.
69. Alanio A, Sitterlé E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66: 371-374. This paper shows low prevalence of azole resistance in a population at risk of invasive aspergillosis, patients treated for hematologic malignancies.
70. Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE. 2010;5:e10080.
71. Verweij PE, te Dorsthorst DTA, Rijs AJMM, et al. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol. 2002;40:2648-50. (Pubitemid 34747381)
72. Verweij PE, Mensink M, Rijs AJ, et al. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother. 1998;42:389-92. (Pubitemid 28442454)
73. Dannaoui E, Borel E, Monier MF, et al. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2001;47:333-40. (Pubitemid 32229575)
74. Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med. 2002;347:2173-4.
75. Chen J, Li H, Li R, et al. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55:31-7. (Pubitemid 40192611)
76. Snelders E, Huis in't Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053-7.
77. Mortensen KL, Mellado E, Lass-Flörl C, et al. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010;54:4545-9.
78. Leroux P, Albertini C, Gautier A, et al. Mutations in the CYP51 gene correlated with changes in sensitivity to sterol 14 alphademethylation inhibitors in field isolates of Mycosphaerella graminicola. Pest Manag Sci. 2007;63:688-98. (Pubitemid 47025963)
79. Meneau I, Sanglard D: Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 2005; 43 Suppl 1: S307-11. This paper demonstrated that A. fumigatus isolates resistant to itraconazole were cross-resistant with azole pesticides, reinforcing the possibility of environmental acquisition of resistance. (Pubitemid 41038583)
80. Snelders E, Camps SM, Karawajczyk A, et al. Azole-resistance in Aspergillus fumigatus: collateral damage of fungicide use? Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Milan, Italy: May 7-10, 2011.
81. Délye C, Laigret F, Corio-Costet MF. A mutation in the 14 alphademethylase gene of Uncinula necator that correlates with resistance to a sterol biosynthesis inhibitor. Appl Environ Microbiol. 1997;63:2966-70. (Pubitemid 27337780)
82. Wyand RA, Brown JKM. Sequence variation in the CYP51 gene of Blumeria graminis associated with resistance to sterol demethylase inhibiting fungicides. Fungal Genet Biol. 2005;42:726-35. (Pubitemid 40848643)
83. Meersseman W, Lagrou K, Maertens J, et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205-16. (Pubitemid 47044802)
84. Falcone M, Massetti AP, Russo A, et al. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011;49:406-13.
85. Trof R, Beishuizen A, Debets-Ossenkopp Y. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007;33:1694-703. (Pubitemid 47476659)
86. Mortensen KL, Johansen HK, Fuursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011 May 4 (Epub ahead of print).
87. Baddley JW. Clinical risk factors for invasive aspergillosis. Med Mycol. 2011;49 Suppl 1:S7-S12.
88. Bow EJ. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol. 2008;140:133-52. (Pubitemid 350284490)
89. Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94:113-22.
90. van der Linden J, Snelders E, Kampinga G, et al. Prospective surveillance of azole-resistance in Aspergillus fumigatus in the Netherlands. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Milan, Italy: May 7-10, 2011.
91. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683. This paper presents recommendations for evaluating the responses to therapy of invasive fungal infection, including aspergillosis.
92. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481-3.
93. Lamaris GA, Ben-Ami R, Lewis RE, et al. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. J Antimicrob Chemother. 2008;62:539-42.
94. Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51:1383-91.